Relevium Announces Agreement with Neptune Wellness for MaxSimil®
Momentum Public Relations
Press Release: April 30, 2019
Relevium Technologies Inc. (TSX.V:RLV), (OTCQB:RLLVF) and (Frankfurt:6BX) (the“Company” or “Relevium”), is pleased to announce the signing of a product development, supply and commercialization agreement with Neptune Wellness Solutions (TSX:NEPT) (NASDAQ:NEPT) for MaxSimil®, a patented fish oil monoglyceride omega 3 technology.
Highlights
- MaxSimil® is a technology that enhances the absorption of lipid and lipid-soluble ingredients in the production of nutraceuticals
- The agreement includes product development, supply and commercialization for Canada and USA
- Initial 2-year term
- Development of two (2) products in year one and an additional six (6) within year two
- The agreement includes Research and Development contribution by Relevium in the form of a 2.5% royalty on net sales payable to Neptune quarterly
Aurelio Useche, Relevium’s CEO “We are very pleased to partner with Neptune Wellness to develop new formulations combining MaxSimil® technology with plant derivatives and other nutraceutical ingredients, which will form part of current and future exclusive science-based brands” Mr. Useche continued: “The MaxSimil technology could prove to be a real differentiator for products marketed through our subsidiaries BGX Health and Biocannabix Health and their brands”
Francois-Karl Brouillette, Neptune’s VP, Science and Innovation stated:” Relevium’s business and product development strategies will be great accelerators to Neptune’s own MaxSimil® nutraceutical development program. Free of any unwanted excipients and mimicking our natural biological system, MaxSimil technology is an efficient nutraceutical-type delivery system that is perfectly compatible with today’s dietary supplement industry.” Mr. Brouillette added: “I strongly believe that this exciting new partnership will help us further unlock this patented technology’s full potential while extending its reach to a broader consumer base.”
About MaxSimil®
MaxSimil is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals. MaxSimil mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as plant and fish derived oils.
About Neptune Wellness Solutions
Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company formulates and provides turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products. The Company’s head office is located in Laval, Quebec.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses and entrepreneurial brands in the growing health and wellness sector. The Company creates value by building brand equity, organic product offering and geographic expansion. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook, Follow us on Twitter
and Follow us on LinkedIn
- Published in Relevium Technologies
Sirona Biochem to Exhibit at the Shanghai China Beauty Expo 2018
Momentum Public Relations
Press Release: April 30 2018
Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that they will be exhibitors at China Beauty Expo (CBE) 2018. The trade show will be held May 22-24 in Shanghai, a growing hub in the cosmetic space.
The China Beauty Expo is the lead international beauty trade fair, providing a platform for key professionals in the cosmetic industry to meet and collaborate to enter the Asian market. Asia is currently the biggest market for beauty personal care ingredients and China specifically is the second biggest cosmetic market, with continued double-digit growth. The company looks forward to meeting with professionals from over 30 countries and discussing partnering opportunities.
As a member of the Cosmetic Valley, the company will also benefit from press and advertisement campaigns before, during and after the show. All exhibitors from the Cosmetic Valley will be part of the media promotional campaign for China Beauty Expo, along with featured pages in all show material including the May edition of Cosmetic News, which is sent out to 100,000 industry professionals in China. Sirona Biochem would like to extend their gratitude to the Normandy District and the Normandy Development Agency for sponsoring the trip.
While Sirona continues in its negotiations with a lead global partner alongside advanced due diligence from other partners, Sirona Biochem aims to expand its corporate presence in the Asian market. The company believes that its platform technology and pipeline will be of great interest to the CBE attendees, especially within the expanding Asian market.
“Ultimately, management’s responsibility is to bring as many players to the table to create a competitive environment on a licensing deal for 1067 and will continue such efforts until a definitive agreement is concluded,” said CEO, Dr. Howard Verrico.
With the extensive family of skin-lighteners within Sirona’s portfolio and novel LIP-01 anti-wrinkle compound, Sirona Biochem is well-positioned to meet the needs of the Asian consumers.
About China Beauty Expo
In its 23rd year, this show attracts a variety of beauty professionals, including importers, distributors, retailers and even beauty salons. Exhibitors are categorized by cosmetech, cosmetics and professional beauty.
In 2017, there were over 400,000 attendees from around the globe, including China, Korea, and the USA. This year, an anticipated 500,000 visitors will attend, alongside the 3,500 exhibitor booths. More specifically, there will be 1000 international brands from over 34 countries. Sirona Biochem will be one of the exhibitors within the Cosmetic Valley section.
For more information, visit: https://www.chinabeautyexpo.com/en/homepage.html
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Alliance Mining Reports Drilling Complete on Packsack Property, Bisset, Manitoba
Momentum Public Relations
Press Release: April 26 2018
Alliance Mining Corp. (TSX-v: ALM) (“Alliance” or the “Company”) is pleased to report that drilling is complete on its Packsack property, part of the Red Rice Lake gold project. All drill core has been logged and core sawing/sampling is presently underway. Core size was NQ.
The program was completed with four drill holes totaling 792.9 meters. Locations (UTM NAD83 Zone 15) and drill hole orientations are tabulated below. All technical objectives of the program were accomplished.
Drill Hole # | Collar Coordinates | Orientation | Total Depth |
PK-18-1 | 310061E / 5652811N | -55° / 205°az | 80ft / 24.4m |
PK-18-2 | 310018E / 5652760N | -65° / 205°az | 1247ft / 380.1m |
PK-18-3 | 310037E / 5652739N | -70° / 180°az | 887ft / 270.4m |
PK-18-4 | 310001E / 5652695N | -48° / 220°az | 387ft / 118.0m |
Drill hole PK-18-1 was abandoned without casing into bedrock when unexpectedly deep overburden was encountered along the north side of the Red Rice Lake topographic lineament, which lies immediately north of the Packsack vein systems. Drilling was then shifted to the south side of the lineament. Drill setup locations along the south side of the lineament are constrained by beaver ponds, underground drifts/crosscuts and rock dumps. Future drilling from the north side of the lineament will start with HQ to ensure casing to bedrock.
Drill hole PK-18-2 was drilled beneath the Packsack veins and underground drifts/crosscuts. This drill hole intersected sericite-altered and quartz-veined feldspar porphyry dike mineralized with 1% pyrite at 104.84 to 110.48m, as well as chlorite-altered and quartz-veined mafic dike mineralized with 2% pyrite at 113.35 to 126.42m. These sections are believed to be en echelon northerly extensions of the Packsack vein systems. Core angles of 35 to 40° suggest true widths will be approximately 60% in these sections (see photograph below).
To view the graphic in its original size, please click here
PK-18-2 also intersected sericite-altered and quartz-veined dacite volcanics with 1% pyrite at 316.73 to 318.11m and at 328.57 to 356.20m. Core angles averaging 20° suggest true widths of about 35% in these sections. These intersections are believed to be the down-plunge extension of the Tine veins, which outcrop about 300m south of the Packsack shaft. The Tine veins were not a primary target of this program (see photograph below).
To view the graphic in its original size, please click here
Drill hole PK-18-3 was intended to test for a possible east to northeasterly plunge of the Packsack vein systems. This drill hole intersected sericite-altered quartz-veined dacite volcanics with 2% pyrite at 159.58 to 161.95m. Core angles of 30° suggest 50% true width. This drill hole suggests that the Packsack vein systems do not plunge significantly to the east or northeast, consistent with observations of a possible northerly en echelon pattern from hole PK-18-2.
Drill hole PK-18-4 was intended to intersect the Big Dome vein between the -125ft (38m) level and -250ft (76m) drifts/crosscuts, in order to provide gold grade/width data on the portion of the vein which was explored by underground exploration in the 1930s. This drill hole intersected sericite-altered and silicified dacite volcanics with minor pyrite at 38.10 to 46.33m (true width 70%), likely the Hargreaves vein. The Big Dome vein was intersected from 56.80 to 65.38m and was characterized by a 50% mix of quartz-calcite-ankerite-tourmaline veining with 1% pyrite and sericite-altered mafic dike wallrock with 3% pyrite. Core angles on the Big Dome vein varied widely but averaged 30° suggesting a 50% true width (see photo below). Variable sericite alteration and quartz-calcite-ankerite-tourmaline veining continued in both altered dacite and altered mafic dikes with 1 to 2% pyrite at 65.38 to 90.09m and 112.61 to 115.59m with core angles averaging 45° suggesting 70% true widths.
To view the graphic in its original size, please click here
“These geological/mineralogical characteristics are indicative of a very promising environment for gold exploration,” stated consulting geologist William Hood.
Alliance Mining has an option to acquire 100 per cent of the Red Rice Lake property located in the centre of the Bissett gold camp in Manitoba. The property is located close to the town of Bissett, Man., and just four kilometres south from Klondex Mines’ True North gold mine. The Red Rice Lake gold property claims are located within the Archean Rice Lake greenstone belt in southeastern Manitoba. This belt forms part of the Uchi sub province that includes the Red Lake and Pickle Lake belts in Northwestern Ontario.
Alliance is actively seeking to expand its presence in the Bissett Gold camp through future property acquisitions and/or potential joint venture exploration partnerships with neighbouring companies.
William C. Hood, P.Geo, a qualified person as defined by National Instrument 43-101, is responsible for the technical information contained in this news release.
ON BEHALF OF THE BOARD
Mr Christopher Anderson
President, CEO and Director
FOR FURTHER INFORMATION PLEASE CONTACT:
Alliance Mining Corp.
(604) 488-3900
Investor Relations:
Antony Claydon: 604-445-5421
E-mail: ir@alliancemining.com
This press release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address future exploration drilling, exploration activities and events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include exploitation and exploration successes, continued availability of financing, and general economic, market or business conditions.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Alliance Mining Corp.
888 Dunsmuir Street – Suite 888, Vancouver, B.C., V6C 3K4
To view the original release (with media), please click here
- Published in Alliance Mining
Relevium Creates Cannabis Brands for North-American Market
Momentum Public Relations
Press Release: April 26
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of its two first cannabis brands, LeefyLyfe and Biocannabix offering cannabis products in the North-American and European markets. LeefyLyfe and Biocannabix brands are part of the wholly owned Biocannabix Health Corporation (the “Subsidiary” or “BHC”).
Highlights
- Biocannabix® will target the Canadian market pursuant to ACMPR regulations
- LeefyLyfe® will target CBD sales outside of Canada in full compliance with local legal and regulatory framework
- All resources being pooled to fast track the company’s positioning in the cannabis space
Aurelio Useche, CEO of Relevium stated: “We believe the organizations that build credible, trusted and recognizable brands in the CBD market will be the winners in this already fragmented space. At RLV, we are leveraging our current branding and online abilities in combination with all the resources at our disposal internally and externally to position the Company in the consumer products cannabis space.” Mr. Useche continued: “From formulation to branding and e-retail, we will be able to monetize CBD and CBG based consumer products outside of the Canadian market while the application for an ACMPR license for Canada is being worked on. We believe that this approach provides the best balance of short and mid-term ROI and an ideal risk ratio.”
Biocannabix
Relevium will be building the Biocannabix® brand in for the Canadian market and focus the brand architecture towards the medical and health markets. The Company has secured http://biocannabix.com/as the domain for the brand.
In order to gain access to the cannabis for medical purposes market and obtain the necessary licenses from Health Canada, including the ACMPR license, the Company has begun the process of evaluating locations in Quebec that could accommodate the operation. The Company has studied industry peers and believes that with the amount of data available it will be able to act swiftly and in a very cost-effective manner.
LeefyLyfe
Relevium will be building LeefyLyfe® as an elevated and trusted brand for the health-conscious consumer outside of Canada, with a focus on full spectrum hemp, CBD and CBG formulations aimed for lifestyle, health and wellness. The product offering targetsapplications ranging from pain relief and anti-inflammation to anxiety and sports performance. The Company has secured http://leefylyfe.com/ as the domain for the brand.
Relevium has already shortlisted production partners that would be able to meet stringent legal and compliance guidelines. All products being contemplated for the LeefyLyfe® brand will be derived from American grown, organic and non-genetically modified hemp.
The Company projects sales for LeefyLyfe® to commence in Summer in full compliance with rules, regulations and laws at the State and Federal levels.
Building a Brand Portfolio
In full alignment with the company’s business strategy, management is engaged in a process to secure branding licensing agreements and endorsement opportunities tailored for different consumer segments in this market. As opportunities arise, they will be subject to focus group and SWOT analysis in order to evaluate a proper risk/reward for the Company. The Company anticipates having a high-end premium or luxury brand offering in the spring or summer depending on a variety of factors.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Albert Mining Inc. to use Artificial Intelligence (AI) over the Flin Flon Mining Camp, Manitoba-Saskatchewan
Momentum Public Relations
Press Release: April 24, 2018
Albert Mining Inc. (“Albert Mining” or “Corporation”) (TSX-V: AIIM), a mining exploration company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques in the mining sector, is pleased to announce the initiation of the Flin Flon-Snow Lake project covering a swath of west-central Manitoba and eastern Saskatchewan. The work will be done internally using CARDS (Computer Aided Resources Detection System), an Artificial Intelligence tool (Machine Learning). The area being investigated covers 13,708 km2 and is prospective for a number of mineral deposit types, particularly bimodal-felsic VMS (Cu-Zn-Ag-Au-rich) deposits. It lies within the Flin Flon belt, one of the largest Proterozoic volcanic-hosted massive sulphide district in the world, containing 27 Cu-Zn-(Au) deposits from which more than 162 million tons of sulphide have already been mined or are in development
The work will consist of compilation, merging, and processing of all the available public geophysical, geological, geochemical, and topographical data from the Geological Survey of Canada, the iMaQs (Ministry of Innovation, Energy and Mines of Manitoba) and SMAD (Saskatchewan Mineral Assessment Database) databases. A total of 19,379 projected assays (Au, Ag, Cu, Zn) from 5,620 drill holes (DDH) and 166 mineral occurrences (Au, Ag, Cu, Zn) were digitized by Albert Mining’s team. The data from some 1,670 assessments reports, as well as from two datasets comprising 370 and 692 variables (5,483,197 and 3,381,749 data points), respectively, provided from the merging by Albert Mining of public magnetic and electromagnetic data at 50m resolution, will be analyzed through two models by CARDS (Computer Aided Resource Detection System) to identify new targets with signatures similar to known areas of Au, Ag, Cu, Zn mineralization.
Mr. Michel Fontaine, President & CEO of Albert Mining, stated: “The best place to find a mine is close to a mine. This is exactly what we are doing in the Flin Flon area. CARDS will be able to analyze large public geophysical, geochemical, and geological data sets available for the Flin Flon-Snow Lake project in order to discover hidden patterns. The new Au, Ag, Cu, Zn exploration targets generated by Albert Mining will be sold to local exploration mining companies, staked, and the best grassroots targets will be followed up.”
About Albert Mining Inc.
Albert Mining is a junior mining exploration company using 100% Artificial Intelligence (AI) to generate mining projects with an extensive portfolio of gold, copper and diamond properties in Quebec. Albert Mining also recently acquired all assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert Mining can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, and mathematics. The Company’s objective is to develop a new royalty stream by significantly enhancing and participating in the exploration success rate of mining.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Fax: 613-422-0773
Email: michel@albertmining.com
Website: www.albertmining.com
Albert Mining-Powered by Artificial Intelligence
Additional information about the Company is available under Albert Mining’s profile on SEDAR atwww.sedar.com .
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or are events or conditions that “will”, “would”, “may”, “could” or “should” occur or be achieved. This news release contains forward-looking statements, pertaining to, among other things, the following: the resumption of the trading of Albert shares on the TSX Venture Exchange. Statements regarding future production, capital expenditures and development plans are subject to all of the risks and uncertainties normally incident to the exploration for and development and production of oil and gas that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These risks include, but are not limited to, inflation or lack of availability of goods and services, environmental risks, drilling risks, regulatory changes and certain other known and unknown risks detailed from time to time in Albert Mining’s public disclosure documents, copies of which are available on Albert Mining’s SEDAR profile at www.sedar.com .
Although Albert Mining believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. Albert Mining’s actual results may differ materially from those expressed or implied in forward-looking statements and readers should not place undue importance or reliance on the forward-looking statements. Statements including forward-looking statements are made as of the date they are given and except as required by applicable securities laws, Albert Mining disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Uncategorized
Tetra Bio-Pharma Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel
Momentum Public Relations
Press Release: April 24
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.
Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.
About PPP001
On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.
About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
bob@tetrabiopharma.com
M: +1 514 817-2514
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556
- Published in Tetra Bio Pharma
Pacton Gold Announces $4 million Private Placement
Momentum Public Relations
Press Release: April 23 2018
Pacton Gold Inc. (TSXV: PAC, OTC: PACXF) (the “Company” or “Pacton“) is pleased to announce that it has entered into an agreement with Sprott Capital Partners to act as lead agent (the “Lead Agent“), on its own behalf and, if applicable, on behalf of a syndicate of agents (collectively with the Lead Agent, the “Agents“), in connection with a marketed private placement of up to 17,400,000 Units (hereinafter defined) of the Company, at a price of $0.23 per Unit, for gross proceeds of up to $4,002,000 (the “Offering“).
Each Unit will consist of one common share of the Company (a “Common Share“) and one transferable common share purchase warrant (a “Warrant“)(collectively, a “Unit“). Each Warrant will entitle the holder to acquire one Common Share for a period of three years from the date of issue at a price of $0.35.
In connection with the Offering, the Agents will be entitled to a cash fee in an amount equal to 6.0% of the gross proceeds of the Offering. As additional consideration, the Company will grant to the Agents that number of Agent Units (hereinafter defined) that equals 6.0% of the aggregate number of Units placed by the Agents in the Offering. Each “Agent Unit” will consist of one Common Share and one non-transferrable common share purchase warrant (“Agent Warrants“). Each Agent Warrant will permit the purchase of one Common Share for three years from the Closing Date at C$0.35.
The net proceeds from the Offering will be used for exploration work to be conducted on the Company’s properties in Canada and Australia and for general working capital. All of the securities sold pursuant to the Offering will be subject to a four month hold period which will expire four months and one day from the date of issue in accordance with applicable securities laws. The Offering is subject to acceptance of the TSX Venture Exchange.
The Offering may close in one or more tranches, with a final closing no later than May 22, 2018 or such other date or dates as the Company and the Lead Agent may agree.
ON BEHALF OF THE BOARD OF DIRECTORS,
Alec Pismiris
Interim President & CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
This news release includes certain forward-looking statements concerning the use of proceeds of the Offering, the future performance of our business, its operations and its financial performance and condition, as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the future tax treatment of the Flow-Through Shares, competitive risks and the availability of financing, as described in more detail in our recent securities filings available at www.sedar.com. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
SOURCE Pacton Gold Inc.
View original content: http://www.newswire.ca/en/releases/archive/April2018/23/c8737.html
Contact:
please contact 1-(855)-584-0258 or dom@pactongold.com.
- Published in Pacton Gold Inc., Uncategorized
ATW Tech Announces Completion of Einsteinium Cryptocurrency Integration Phase I
Momentum Public Relations
Press Release: April 20 2018
ATW Tech (“AtmanCo” or the “Company”) (TSX VENTURE:ATW) is proud to announce, as part of its ongoing global partnership with the Einsteinium Foundation (“EMC2”) (refer to press release dated January 12, 2018) that the first phase of its implementation has been completed for the integration of blockchain technology into its various platforms, which include voting, gaming and fundraising. ATW Tech’s subsidiary, Voxtel, has begun accepting the cryptocurrency as a payment solution on its unified payment platform.
Alongside the other channels of distribution and development targeted such as the further integration on Voxtel’s payment gateway to buy, exchange or transfer Einsteinium coins, and peer-to-peer network gaming, being a leader in mobile political voting and mobile fundraising in Canada, Voxtel will also focus on the political arena and is planning to launch crypto contributions in the Fall of 2018.
“We’ve been looking at crypto for quite some time,” says Michel Guay, CEO of ATW Tech, adding that: “Many organizations are getting in on the cryptocurrency craze for example to fund political campaigns and we want to be the first facilitator.”
“Using Einsteinium for fundraising efforts has the distinct advantage of creating transparency in an area where it is needed most.” says Ben Kurland, Chief Strategist of the Einsteinium Foundation. “Furthermore, it can be far more efficient than other payment solutions due to its speed, security and ability to be transferred internationally.”
Einsteinium is a blockchain currency designed to democratize research funding. The Einsteinium Foundation which maintains the currency and furthers its utility and adoption, is due to launch a crowdfunding platform to promote scientific research in June. Other recent developments include a social mobile wallet and the first annual Einsteinium Awards set to take place in September.
Additional information regarding the Company is available on SEDAR www.sedar.com. The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT emc2
The emc2 coin is a Bitcoin-like currency with a philanthropic objective of funding scientific research, cutting edge IT and crypto currency projects. The emc2 coin is released by the Einsteinium Foundation. emc2 is embarking on a truly ambitious project that will likely change how cryptocurrency (“CC”) is viewed outside of the CC universe. Similar to the Bitcoin, Einsteinium is a distributed peer-2-peer digital currency released without any premium. EMC2 implements the primary innovation of wormhole mechanics to reward long term miners. Each wormhole event occurs randomly during each epoch and is 180 blocks long, with a reward of 2970 emc2 per block.
ABOUT ATW TECH
ATW Tech (‘AtmanCo’) (TSX-V:ATW) is a leader in information technology, owner of several web platforms including VoxTel, Québec Rencontres, VuduMobile, Atman and Bloomed. VoxTel offers various interactive landline and mobile carrier billing phone solutions. Quebec Rencontres is a web and mobile social network application catered to building serious and sustainable relationships. VuduMobile is specialized the text messaging business for enterprises through its unique, user-friendly and bilingual test messaging application et turnkey solution allowing management of text message management programs in all kind of businesses. Atman and its APIs enable companies to optimize their human capital. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors, which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW TECH (“AtmanCo”) | |
Michel Guay | Simon Bédard, CA, CPA, CFA, MBA |
Founder, president and CEO | CFO |
Tel.: 514.935.5959 ext. 301 | Tel. : 514.935.5959 ext. 304 |
mguay@atmanco.com | sbedard@atmanco.com |
www.atwtech.com |
- Published in ATWTECH
ProSmart Closes $1,381.204.30 Non-Brokered Private Placement, Announces $1.75 Million Brokered Private Placement and Announces Issuance of Shares Under Services Agreement
Momentum Public Relations
Press Release:April 20 2018
ProSmart Enterprises Inc. (TSXV:PROS) (“ProSmart” or the “Company”), a global online network, connecting sports fans, teams and brands, is pleased to announce that it has closed the non-brokered private placement (the “Non-Brokered Offering”) announced on March 20, 2018 and is launching a brokered private placement (the “Brokered Offering”) led by Mackie Research Capital Corporation (“Mackie”).
Due to significant demand from investors associated with Mackie, ProSmart has decided to close on $1,381,205.49 of the proposed $2.1 million Non-Brokered Offering and has engaged Mackie to lead the Brokered Offering of up to $1.75 million. Both offerings (together, the “Offerings”) are for units with identical terms as described below. Mackie currently anticipates closing (the “Closing”) of the Brokered Offering shall take place on or about the week of April 30, 2018. Should the Brokered Offering close on the full $1.75 million, the Offerings would raise a combined total of $3,131,205, reflecting strong demand from investors.
The net proceeds from the Offerings will be used for general working capital purposes, funding of a fully integrated IR and marketing campaign and upgrading the technology platform through the software development agreement with Firestitch Inc. (“Firestitch”) announced on March 8, 2018.
Says Alan Schuler, CEO and Co-founder of ProSmart, “We are thrilled to see such strong demand for the Offerings and are especially pleased with the additional support that Mackie has offered to provide the Company. Mackie is one of Canada’s largest independent brokerage firms, with a full team of financial advisors and investment bankers, as well as institutional sales, trading and research professionals. This relationship will be very beneficial for us as we look to grow from a small cap company into something much larger.”
Description of Units
The units (the “Units”) for the Offerings are priced at $0.35 per Unit. Each Unit consists of one common share in the capital of the Company (a “Share”) and one transferable common share purchase warrant (a “Warrant”), with each Warrant exercisable into one additional Share at a price of $0.45 for a period of two years from closing.
The Company has the option to force conversion through an acceleration clause (the “Acceleration Clause”). The Acceleration Clause gives the company the right beginning on the date that is four months plus one day following closing, in the event that the weighted average daily trading price of the Shares on the TSX Venture Exchange (the “TSXV”) is $0.55 or more per Share for 10 consecutive trading days, in which case the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof (by disseminating a press release advising of the acceleration of the expiry date of the Warrants) and, in such case, the Warrants will expire on the thirtieth day after the date of such notice.
Non-Brokered Offering
ProSmart closed the sale of 3,946,298 Units for gross proceeds of $1,381,204.30 on April 20, 2018. All securities issued in connection with the closing of the Non-Brokered Offering are subject to a statutory hold period of four months plus one day in accordance with applicable securities legislation expiring on August 21, 2018. The Warrants issued in connection with the Non-Brokered Offering expire on April 20, 2020 and the Acceleration Clause for these warrants can be exercised on or after August 21, 2018.
In connection with the closing of the Non-Brokered Offering, ProSmart paid finder’s fees totaling $5,045.01 in cash and issued 14,414 non-transferable finders warrants (the “Finders Warrants”). Each Finders Warrant is exercisable into one Share at a price of $0.45 for a period of two years, expiring on April 20, 2020. The Finders Warrants are also subject to the Acceleration Clause.
The Non-Brokered Offering is subject to the final acceptance of the TSXV.
Brokered Offering
Mackie is acting as lead agent and sole bookrunner, on a best-efforts basis, for the Brokered Offering of up to 5,000,000 of Units resulting in gross proceeds of up to $1,750,000. The Company has granted Mackie an option (the “Agent’s Option”) exercisable at any time up to and including Closing to increase the size of the Brokered Offering by up to 15% in Units by giving written notice of the exercise of the Agent’s Option, or a part thereof.
The Brokered Offering will take place by way of a private placement to qualified investors in the provinces of Alberta, British Columbia, and Ontario, and otherwise in those jurisdictions where the Brokered Offering can lawfully be made, including the U.S., under applicable private placement exemptions. The Brokered Offering is subject to the acceptance of the TSXV and all securities issued thereunder will be subject to a statutory hold period of four months plus one day under applicable securities legislation.
At Closing, the Company will pay to Mackie a cash commission of 8% of the aggregate gross proceeds arising from the Brokered Offering (the “Commission”), such Commission also being applicable on gross proceeds arising from the exercise of the Agent’s Option, where any such exercise occurs. At Closing, and subject to regulatory approval (where any such approval is required), Mackie will receive options (the “Compensation Options”) exercisable at any time up to two years following Closing to purchase broker units (the “Broker Units”) of the Company in an amount equal to 8% of the number of Units sold in connection with the Brokered Offering, including the amount subscribed for pursuant to the exercise of the Agent’s Option, where any such exercise occurs. The Compensation Options shall be exercisable at the price of $0.35 per Broker Unit. Each Broker Unit is comprised of one Share and one non-transferable broker warrant (the “Broker Warrant”). Each Broker Warrant is exercisable into an additional Share at $0.45 for two years from the Closing subject to the Acceleration Clause. The Company shall also pay to Mackie a non-refundable work fee of $35,000 and a payment for advisory services to be satisfied upon the issuance of 100,000 Shares of the Company at the transaction price of $0.35 per Share. The certificate representing such Shares will include a legend indicating that such Shares are subject to a statutory hold period of four months plus one day.
The Brokered Offering is subject to certain conditions, including, but not limited to, completion of satisfactory due diligence and receipt of all necessary regulatory approvals, including the acceptance of the TSXV.
Shares for Services
The Company announces that it has issued 84,885 Shares to Firestitch in payment of an invoice issued under the software development agreement previously announced on March 8, 2018 and approved by the TSXV on March 26, 2018. The invoice owing to Firestitch is in the amount of $54,156.75. The number of Shares to be issued is based on a deemed price of $0.638 per Share, calculated as the average price per Share on the TSXV for the five days subsequent to the end of the month in which the services were performed.
Alan Schuler
Co-Founder & Chief Executive Officer
About ProSmart Enterprises Inc.
ProSmart (TSX-V:PROS) is a global online network connecting sports fans, teams and brands and is an emerging leader in sports content marketing through online tools and mobile apps. ProSmart works with over 1,500 governing bodies in more than 100 countries and provides unprecedented access to the $1.3 trillion sports market through its proprietary marketplace engine. ProSmart is also the first-and-only company to provide educational content created exclusively by hall-of-fame and professional athletes, which has been a key driver in building the company’s online network and connecting with youth, amateur and professional sports fans and players. ProSmart is a publicly traded company listed on the TSX-V.
For more information on ProSmart and its platforms, please visit the following links:
ProSmart Inc.: http://prosmartinc.com
RosterBot Inc.: http://rosterbot.com
ProSmart Hockey: http://prosmarthockey.com
ProSmart Football (Soccer): http://prosmartfootball.com
Stay connected with ProSmart by following us on:
LinkedIn (www.linkedin.com/company/prosmartsports)
CrunchBase (www.crunchbase.com/organization/prosmart-sports-development-inc)
AngelList (www.angel.co/prosmart-sports-development)
For further information please contact:
Ty Summach, Chief Operating Officer
t: 1-844-927-6278 ext. 103
e: investment@prosmartsports.com
The shares of ProSmart Enterprises Inc. trade publicly on the TSX Venture Exchange under the symbol TSXV:PROS.
“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
To view the original release, please click here
Source: ProSmart Enterprises Inc. (TSX Venture:PROS, FWB:1R6)
To follow ProSmart Enterprises Inc. on your favorite social media platform or financial websites, please click on the icons below.
- Published in Prosmart Enterprises
Relevium Creates Biocannabix Subsidiary and Targets Legal Cannabis Business
Momentum Public Relations
Press Release: April 19 2018
Relevium TechnologiesInc. (TSX VENTURE:RLV) (OTCQB:RLLVF) (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of Biocannabix Health Corporation (the “Subsidiary” or “BHC”), a Canadian wholly owned subsidiary structured to lead the development of the legal cannabis derivatives business for RLV. The Company projects to complete its ACMPR application for the Canadian marketplace within the current fiscal quarter and has begun to assemble its legal and regulatory team of experts within targeted jurisdictions.
Highlights
- Biocannabix Health Corporation to lead the Company’s legal cannabis initiatives
- Focus on developing a portfolio of high end consumer brands for North America
- Prepare for a global online marketplace for jurisdictions with a legal context
- Subsidiary anticipates applying for the necessary ACMPR licenses from Health Canada
- Initial commercial focus will be on industrial hemp derivatives such as CBG and CBD
As a Canadian company, Relevium will initially target the legal cannabinoids markets in North-America and develop medical, lifestyle and luxury consumer products aimed at supporting overall health and wellness. The Company’s newly created subsidiary is expected to begin the process of obtaining access to cannabis for medical purposes through the filing of an application for the appropriate licences from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The primary purpose of the application will be to enable the Company, through Biocannabix, to secure the appropriate legal authorizations to be able to distribute and sell medical cannabis products in Canada and service other jurisdictions in the export market.
Aurelio Useche, CEO of Relevium stated: “Our core business is health and wellness and the legal Cannabis derivative business is growing exponentially in our niche. In the US, relaxing regulations and a fragmented market place represent a true opportunity to build elevated and trusted cannabinoid derivative consumer brands”. Mr. Useche continued: “In the industrial hemp derivatives space there is rapid proliferation of cannabinoids-based products like CBG and CBD. The challenge, however, is Branding, Quality and Customer Experience, all areas that RLV intends to leverage through its channel expertise.”
The Company’s strategic direction is very much in-line with its core business, which includes the creation of a portfolio of online, direct to consumer retail brands in Health and Wellness, both organically, through licensing agreements and via acquisitions.
The Company understands this is a fast-evolving regulatory environment. In order ensure the adoption of a full legal and compliant framework, the Company is assembling a team of legal and business experts from the space.
About the Market
According to a report from Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is expected to reach $63.5 billion in 2024, growing at a compound annual growth rate of 21.1 percent during the forecast years. North America accounts for over 49% of the market, with the U.S. being the single largest market.
A Major segment of the legal cannabis industry is the hemp-derived cannabidiol (CBD) market. According to a report by Forbes, Brightfield Group projects that Hemp-derived cannabidiol (CBD) will be a billion-dollar market in just three years. CBD products do not have any psychotropic effects and are usually used for medical purposes. Brightfield’s data estimates that hemp CBD sales have already hit $170 million in 2016 and at a 55% compound annual growth rate over the next five years the market will cross the billion-dollar mark. According to Statista, it is estimated that in the year 2020 CBD consumer sales will total around 1.15 billion U.S. dollars. Brightfield determined that 64.5% of the sales come through the online channel followed by 17.8% from physical points of sale.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies